Stock CRSP CRISPR THERAPEUTICS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
53.91 USD +0.34% Intraday chart for CRISPR Therapeutics AG -2.07% -13.88%
18/04 Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating MT
17/04 Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,621 10,818 5,799 3,183 4,972 4,576 - -
Enterprise Value (EV) 1 2,677 9,649 3,420 1,367 3,277 3,024 3,182 2,401
P/E ratio 52.1 x -28.9 x 15.2 x -4.86 x -32.3 x -9.82 x -12.7 x -26.1 x
Yield - - - - - - - -
Capitalization / Revenue 12.5 x 15,045 x 6.34 x 2,657 x 13.4 x 37.7 x 11.3 x 4.92 x
EV / Revenue 9.25 x 13,420 x 3.74 x 1,141 x 8.83 x 24.9 x 7.88 x 2.58 x
EV / EBITDA 52 x -27.9 x 8.74 x -2.11 x -16.2 x -8.28 x -9.7 x 50.3 x
EV / FCF - -37.6 x 7.48 x -2.57 x -12.1 x -10.7 x -10.1 x -10.3 x
FCF Yield - -2.66% 13.4% -39% -8.24% -9.38% -9.86% -9.74%
Price to Book - 6.94 x 2.4 x 1.69 x 2.63 x 2.55 x 3.07 x -
Nbr of stocks (in thousands) 59,454 70,652 76,527 78,294 79,432 84,883 - -
Reference price 2 60.90 153.1 75.78 40.65 62.60 53.91 53.91 53.91
Announcement Date 12/02/20 16/02/21 15/02/22 21/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 289.6 0.719 915 1.198 371.2 121.5 404 930.3
EBITDA 1 51.46 -345.3 391.5 -649 -202.7 -365.3 -328.2 47.7
EBIT 1 46.74 -354.4 373.5 -673.2 -222.5 -482.5 -357.6 -80.39
Operating Margin 16.14% -49,295.55% 40.82% -56,190.4% -59.95% -397.16% -88.52% -8.64%
Earnings before Tax (EBT) 1 67.31 -348.1 379.5 -650.5 -150.7 -464.1 -378.4 -186
Net income 1 66.86 -348.9 377.7 -650.2 -153.6 -454.3 -381.1 -180.1
Net margin 23.09% -48,520.86% 41.28% -54,271.7% -41.38% -373.91% -94.32% -19.36%
EPS 2 1.170 -5.290 4.970 -8.360 -1.940 -5.489 -4.252 -2.062
Free Cash Flow 1 - -256.7 457.3 -532.9 -269.8 -283.6 -313.9 -233.8
FCF margin - -35,705.7% 49.98% -44,484.89% -72.69% -233.41% -77.69% -25.13%
FCF Conversion (EBITDA) - - 116.8% - - - - -
FCF Conversion (Net income) - - 121.08% - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 12/02/20 16/02/21 15/02/22 21/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.329 12.9 0.94 0.158 0.094 0.006 100 70 - 201.2 25.17 10.99 29.21 46.97 38.48
EBITDA 1 - - - - - - - - - 74.48 85.66 -115.5 -116.5 -112.2 -
EBIT 1 -128.8 -145.7 -176 -183.3 -182.4 -131.5 -64.49 -95.22 -132.4 69.58 -126.3 -138.3 -126.4 -117.5 -125.5
Operating Margin -39,163.83% -1,129.53% -18,720.43% -1,15,987.34% -1,94,029.79% -21,92,350% -64.49% -136.03% - 34.58% -501.68% -1,258.68% -432.67% -250.19% -326.23%
Earnings before Tax (EBT) 1 -127.7 -143.5 -175.6 -179.7 -175.1 -120.1 -51.74 -76.82 -111.7 89.58 -126.8 -125.9 -111.2 -103.5 -115.5
Net income 1 -127.2 -141.2 -179.2 -185.8 -174.5 -110.6 -53.06 -77.74 -112.2 89.35 -127.3 -126.6 -110.9 -102.3 -116
Net margin -38,648.33% -1,095.03% -19,065.64% -1,17,616.46% -1,85,690.43% -18,42,916.67% -53.06% -111.06% - 44.41% -505.67% -1,152.25% -379.73% -217.89% -301.54%
EPS 2 -1.670 -1.840 -2.320 -2.400 -2.240 -1.410 -0.6700 -0.9800 -1.410 1.100 -1.397 -1.511 -1.351 -1.270 -1.278
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 03/11/21 15/02/22 09/05/22 08/08/22 01/11/22 21/02/23 08/05/23 07/08/23 06/11/23 21/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 944 1,169 2,379 1,815 1,696 1,552 1,394 2,175
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -257 457 -533 -270 -284 -314 -234
ROE (net income / shareholders' equity) - -26.8% 18.6% -30.4% -8.17% -21.3% -7.38% 9.53%
ROA (Net income/ Total Assets) - - - -26% -6.87% -14.4% 4.45% 12.2%
Assets 1 - - - 2,497 2,236 3,155 -8,564 -1,477
Book Value Per Share 2 - 22.10 31.60 24.10 23.80 21.10 17.60 -
Cash Flow per Share 2 - -3.610 6.700 -6.380 -3.290 -1.790 0.3300 6.540
Capex 1 - 18.4 81.7 37.2 9.47 12.3 15.9 16.9
Capex / Sales - 2,553.27% 8.93% 3,104.17% 2.55% 10.1% 3.94% 1.82%
Announcement Date 12/02/20 16/02/21 15/02/22 21/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for CRISPR Therapeutics AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
53.91 USD
Average target price
88.12 USD
Spread / Average Target
+63.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CRISPR THERAPEUTICS AG Stock CRISPR Therapeutics AG
-13.88% 4.58B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRSP Stock
  4. Financials CRISPR Therapeutics AG